Abstract 2170
Background
Little is known about the associations between treatment outcome for immune checkpoint inhibitors and metastatic sites in patients with advanced non-small cell lung cancer (NSCLC). Furthermore, these previous studies included patients irrespective of their PD-L1 status and treatment lines. Therefore, we conducted a multicentered retrospective study to investigate the predictive factors of metastatic sites as first-line pembrolizumab efficacy in patients with PD-L1 tumor proportion score (TPS) ≥50% advanced NSCLC.
Methods
We retrospectively analyzed patients with advanced NSCLC and PD-L1 TPS ≥ 50% who received pembrolizumab as the first-line therapy at 11 institutions between February 2017 and April 2018. Clinical data including metastatic sites at the time of administering pembrolizumab treatment were collected. Treatment outcome of pembrolizumab was assessed according to the Response Evaluation Criteria in Solid Tumors, version 1.1.
Results
In total, 213 patients were included in the study. The median age was 71 years (range 39-91). Of the 213 patients, 176 (83%) were men, 172 (81%) had Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1. The major metastatic sites were thoracic lymph nodes metastasis (77%), intrapulmonary metastasis (31%), bone metastasis (28%), and malignant pleural effusion (26%). In multivariate analysis, poor PS (hazard ratio: 1.82, 95.0% confidence interval: 1.15–2.30; P = 0.046) and malignant pleural effusion (hazard ratio: 1.52, 95.0% confidence interval: 1.01–2.30; P = 0.046) was identified as an independent predictor of shorter progression free survival in patients treated with pembrolizumab.
Conclusions
In patients with advanced NSCLC and PD-L1 TPS ≥50% who received first-line pembrolizumab, poor PS and malignant pleural effusion are independent predictors of pembrolizumab efficacy.
Clinical trial identification
UMIN000032470.
Editorial acknowledgement
Legal entity responsible for the study
Hanshin Oncology clinical Problem Evaluation group (HOPE).
Funding
Has not received any funding.
Disclosure
H. Kawachi: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. M. Tamiya: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. A. Tamiya: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. K. Hirano: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. T. Yokoyama: Honoraria (self): Taiho Pharmaceutical Co., Ltd. T. Ishida: Honoraria (self): Merck Sharp & Dohme, Corp. D. Fujimoto: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. T. Hirashima: Honoraria (self): Taiho Pharmaceutical Co., Ltd. M. Kanazu: Honoraria (self): Merck Sharp & Dohme, Corp. T. Kumagai: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. All other authors have declared no conflicts of interest.
Resources from the same session
4925 - Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract
785 - JAK-STAT inhibitor overcomes interferon γ-reduced, NK cell-mediated cytotoxicity in non-small-cell lung cancer cells
Presenter: Riki Okita
Session: Poster Display session 1
Resources:
Abstract
2326 - Low LATS2 expression is associated with poor prognosis in non small cell lung cancer
Presenter: Si-hyong Jang
Session: Poster Display session 1
Resources:
Abstract
5960 - Application of ESCAT and OncoKB scales in Liquid biopsy (LB) in Advanced NSCLC patients (pts): Is it feasible and reliable?
Presenter: Michael McCusker
Session: Poster Display session 1
Resources:
Abstract
4855 - IDH1R132H mutation induces a less aggressive phenotype of glioma cells and affects the radiosensitivity by interacting with Wnt/β-catenin signaling
Presenter: Xuetao Han
Session: Poster Display session 1
Resources:
Abstract
2641 - Impact of Angiopoietin-2 on glioblastoma response to combined chemo-radiotherapy
Presenter: Charly Helaine
Session: Poster Display session 1
Resources:
Abstract
5743 - The Discovery of RNA-aptamers That Selectively Bind and Inhibit Glioblastoma Stem Cells by targeting EphA2
Presenter: Alessandra Affinito
Session: Poster Display session 1
Resources:
Abstract
4160 - Impact of tumor reoxygenation by nanoparticles on Tumor Associated Macrophages (TAMs)
Presenter: Aurélie Ferré
Session: Poster Display session 1
Resources:
Abstract
2474 - Prognostic significance of c-Rel/p50 heterodimer in the tumor microenvironment of uveal melanoma
Presenter: Seema Kashyap
Session: Poster Display session 1
Resources:
Abstract
1769 - Synergistic role of BAP1 and DNA damage response pathway in uveal melanoma and its prognostic significance.
Presenter: JAYANTI JHA
Session: Poster Display session 1
Resources:
Abstract